The U.S. contract research organization (CROs) market is estimated to be valued at US$ 17446.79 Mn in 2023 and is expected to exhibit a CAGR of 9.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Contract research organizations (CROs) provide clinical trial and clinical development services to pharmaceutical, biotechnology, medical device, academic, and government organizations. They support the drug development processes of pharmaceutical companies by providing various clinical trial related services including clinical trial design, clinical operations, data management, regulatory/medical affairs, biostatistics, and medical writing. CROs help pharmaceutical and biotechnology companies reduce development time and costs by giving specialized focus to particular services like clinical research, clinical trials management, data management, biostatistics, and medical writing.
The U.S. CROs market is witnessing high growth owing to increasing demand for outsourcing of clinical trial related services from pharmaceutical and biotechnology companies. Clinical trials are a regulated multi-step process that involves high costs and is labor intensive. Pharmaceutical companies are increasingly outsourcing clinical trial related work as it allows them to focus on their core competencies and reduce development costs and risks. CROs provide expertise across various domains like clinical operations, biostatistics, and regulatory affairs which help accelerate the clinical trial process. Additionally, increasing R&D expenditure on drug development by biopharmaceutical companies is also contributing to the market growth. However, risks associated with data privacy caused by outsourcing clinical trials and stringent regulatory framework may hinder the market growth.
- Strength: The U.S. CROs market has highly skilled professionals with extensive experience in clinical research. Many CROs have a global presence and can facilitate international clinical trials. CROs provide tailored clinical research services and scientific expertise to biotechnology and pharmaceutical companies.
- Weakness: High employee turnover remains a challenge for many CROs. Retaining specialist staff requires competitive compensation and benefits. Regulatory requirements impose substantial compliance costs on CRO operations.
- Opportunity: Growing biosimilars and biologics development provide lucrative opportunities for CROs in the U.S. Emerging markets like Asia and Latin America offer new geographic areas for clinical trial execution.
- Threats: Intense competition exists between large and mid-size CROs for client projects. Price pressures may compress operating margins. Delays in site initiation and subject enrollment pose risks to trial timelines and budgets.
The Global U.S. CROS Market Size is expected to witness high growth, exhibiting CAGR of 9.6% over the forecast period, due to increasing R&D investment in drug development by pharmaceutical companies. Biotechnology and pharmaceutical firms rely on CRO expertise to efficiently advance new therapies from preclinical research to market approval.
The North American region dominates the global CROs market, driven by sizable clinical research budgets in the United States. Presence of top CROs and biopharma companies has made the US a center for clinical trials. Asia Pacific region is projected to grow at the fastest pace during the forecast period, with expanding outsourcing of clinical trials to low-cost locations in China and India.
Key players operating in the U.S. CROs market are Laboratory Corporation of America Holdings (Covance), IQVIA, Paraxel International Corporation, Syneos Health, PRA Health Sciences, Charles River Laboratoires International Inc. (CRL), Pharmaceutical Product Development (PPD), ICON Public Limited Corporation, Wuxi Apptec, Medpace Holdings, Inc, Medidata Solutions, Inc., Theorem Clinical Research, Pharmaron, Envigo, and Clinipace. These firms provide diverse clinical development and laboratory testing expertise to streamline drug approval.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it